Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.